RARE vs TRAK · rev $560.2M vs P/E 25, $167.9M cap
Ultragenyx (RARE) versus ReposiTrak (TRAK) — a side-by-side from cached financials, not a winner call.
Ultragenyx (RARE) is a biotechnology company listed on US.
ReposiTrak (TRAK) is a software - application company listed on NYSE.
Latest reported RARE revenue for 2024-12-31 was $560.2M. Net income was -$569.2M. Revenue was up 29.0% from 2023-12-31 to 2024-12-31. RARE currently screens at market cap $2.79B.
TRAK does not have a complete income-statement cache yet.
RARE currently screens at market cap $2.79B. TRAK currently screens at market cap $167.9M and trailing P/E 25.0.
Not investment advice. Open the RARE and TRAK stock pages for the full models.
Not investment advice.